

• Name:	Raghav Sundar
 Current Position & Affiliation: Country: 	Leader Gastroesophageal Cancer Program, Associate Professor of Medicine (Oncology), Yale University School of Medicine and Yale Cancer Center USA
J ·	

• Educational Background:

- MBBS, Bachelor of Medicine, Bachelor of Surgery National University of Singapore
- MMed, Master of Medicine (Internal Medicine), National University of Singapore
- MCI, Master of Clinical Investigation, National University of Singapore
- PhD, Doctor of Philosophy, National University of Singapore

• Professional Experience:

- Chief Resident, University Medical Centre, National University Health System, Singapore
- Assistant Research Director, Department of Haematology-Oncology, National University Hospital,
- Research Director, Department of Haematology-Oncology, National University Hospital, Singapore
- Deputy Director, Clinician Scientist Development Unit, National University of Singapore, Singapore
- Leader Gastroesophageal Cancer Program, Yale Cancer Center

Professional Organizations:

- American Society of Clinical Oncology
- European Society of Medical Onocology
- International Society of Pleura and Peritoneum
- Multinational Association of Supportive Care in Cancer
- Southwest Oncology Group

• Main Scientific Publications:

[1-24]

- 1. Gwee, Y.X., et al., *Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis.* J Clin Oncol, 2022. **40**(24): p. 2830.
- 2. Ong, J.C., et al., Spatial heterogeneity, stromal phenotypes, and therapeutic vulnerabilities in colorectal cancer peritoneal metastasis. Clin Cancer Res, 2025.
- 3. Zhao, J.J., et al., *Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases*. Gastroenterology, 2024.
- 4. Provenzano, L., et al., Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden. Ther Adv Med Oncol, 2024. **16**: p. 17588359241289517.
- 5. Kim, G., et al., *PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases.* Clin Cancer Res, 2021. **27**(7): p. 1875-1881.



SEP. 3 (WED) – 5 (FRI) | GRAND WALKERHILL SEOUL, KOREA

KSVO 2025

- 6. Chia, D.K.A., et al., Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Ann Surg Oncol, 2022. **29**(13): p. 8597-8605.
- 7. Huang, K.K., et al., *Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression*. Cancer Cell, 2023. **41**(12): p. 2019-2037.e8.
- 8. Kumar, V., et al., Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer. Cancer Discov, 2022. **12**(3): p. 670-691.
- 9. Ma, H., et al., Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution. Cancer Discov, 2025. 15(4): p. 767-792.
- 10. Sundar, R., et al., *Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination*. Gut, 2021. **70**(10): p. 1823-1832.
- 11. Tay, R.Y.K., et al., Spatial organization of B lymphocytes and prognosis prediction in patients with gastric cancer. Gastric Cancer, 2025. **28**(3): p. 384-396.
- 12. An, O., et al., "*3G*" *Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy*. Cancer Res, 2021. **81**(10): p. 2788-2798.
- 13. Blasiak, A., et al., *Personalized dose selection for the first Waldenström macroglobulinemia patient on the PRECISE CURATE.AI trial.* NPJ Digit Med, 2024. 7(1): p. 223.
- 14. Chia, D.K.A., Y.X. Gwee, and R. Sundar, *Resistance to systemic immune checkpoint inhibition in the peritoneal niche.* J Immunother Cancer, 2022. **10**(6).
- 15. Choo, J., et al., *Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer*. Gastric Cancer, 2023. **26**(3): p. 393-404.
- Nargund, A.M., et al., Chromatin Rewiring by Mismatch Repair Protein MSH2 Alters Cell Adhesion Pathways and Sensitivity to BET Inhibition in Gastric Cancer. Cancer Res, 2022. 82(14): p. 2538-2551.
- 17. Senthil Kumar, K., et al., *Artificial Intelligence in Clinical Oncology: From Data to Digital Pathology and Treatment*. Am Soc Clin Oncol Educ Book, 2023. **43**: p. e390084.
- 18. Shitara, K., et al., *Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).* J Cancer Res Clin Oncol, 2023. **149**(11): p. 9361-9374.
- 19. Srikumar, T. and R. Sundar, *Multimodality Treatment for Locally Advanced Gastric Adenocarcinoma*. Surg Clin North Am, 2025. **105**(1): p. 75-94.
- 20. Sheng, T., et al., *Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer.* Genome Med, 2021. **13**(1): p. 158.
- 21. Smyth, E.C. and R. Sundar, *Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer.* Lancet, 2023. **402**(10418): p. 2168-2170.
- 22. Sundar, R., et al., *Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial.* Gut, 2022. **71**(4): p. 676-685.
- 23. Sundar, R., et al., *Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition*. Gut, 2022. **71**(7): p. 1277-1288.
- 24. Sundar, R., et al., Gastric cancer. Lancet, 2025.